Share Capital $’000 Share Option Reserve $’000 Currency Translation Reserve $’000 Accumulated Deficit $’000 Total Equity $’000 Equity as at 1 January 2021 145,567 394 (10,678) (111,083) 24,200 Shares issued in capital raising 20,000 – – – 20,000 Shares issued in share purchase plan 3,281 – – – 3,281 Share issue costs (1,270) – – – (1,270) Share based payments – 840 – – 840 Transactions with owners 22,011 840 – – 22,851 Loss after income tax – – – (7,794) (7,794) Other comprehensive loss – – (4) – (4) Total Comprehensive income for the year – – (4) (7,794) (7,798) Equity as at 31 December 2021 167,578 1,234 (10,682) (118,877) 39,253 Reversal of share issue costs 162 – – – 162 Share based payments – 1,988 – – 1,988 Transactions with owners 162 1,988 – – 2,150 Profit after income tax – – – 184 184 Other comprehensive income – – 2 – 2 Total Comprehensive income for the year – – 2 184 186 Equity as at 31 December 2022 167,740 3,222 (10,680) (118,693) 41,589 The notes on pages 30 to 44 form part of these consolidated financial statements. CONSOL I DATED STATEMENT OF CHANGES I N EQU I T Y FOR T H E Y E A R E ND E D 3 1 D E C EMB E R 2 0 2 2 Neuren Pharmaceuticals Limited Annual Repor t 2022 28
RkJQdWJsaXNoZXIy MjE2NDg3